SBI Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$131K Buy
11,366
+2
+0% +$28 ﹤0.01% 804
2026
Q2
$170K Buy
11,364
+10,360
+1,032% +$144K ﹤0.01% 717
2026
Q1
$14.7K Hold
1,004
– – ﹤0.01% 1582
2025
Q4
$7.73K Sell
1,004
-2
-0.2% -$16 ﹤0.01% 1835
2025
Q3
$7.41K Buy
1,006
+6
+0.6% +$31 ﹤0.01% 1892
2025
Q2
$4K Hold
1,000
– – ﹤0.01% 2094
2025
Q1
$3.18K Hold
1,000
– – ﹤0.01% 2080
2024
Q4
$5.35K Buy
+1,000
New +$7.46K ﹤0.01% 1902

Other funds holding CRVS

SBI Securities's CRVS Position: Q3 2026 in Review

SBI Securities increased its Corvus Pharmaceuticals (CRVS) stake by 0.02% in Q3 2026, buying an estimated $28 and bringing the position to 11,366 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #804.

SBI Securities first reported a position in CRVS in Q4 2024 and has held it in 8 quarters since. The position peaked at $170K in Q2 2026. 177 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • SBI Securities held 11,366 shares of Corvus Pharmaceuticals worth $131K as of Q3 2026.
  • SBI Securities bought 2 Corvus Pharmaceuticals shares in Q3 2026, an estimated $28.
  • Corvus Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #804 holding.
  • SBI Securities first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Corvus Pharmaceuticals position peaked at $170K in Q2 2026.
  • 177 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.